[go: up one dir, main page]

BR0207310A - Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais - Google Patents

Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais

Info

Publication number
BR0207310A
BR0207310A BR0207310-2A BR0207310A BR0207310A BR 0207310 A BR0207310 A BR 0207310A BR 0207310 A BR0207310 A BR 0207310A BR 0207310 A BR0207310 A BR 0207310A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
interstitial lung
pirfenidone
molecular diagnostics
interferon gamma
Prior art date
Application number
BR0207310-2A
Other languages
English (en)
Inventor
Dorian Bevec
Rolf Ziesche
Original Assignee
Mondobiotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Sa filed Critical Mondobiotech Sa
Publication of BR0207310A publication Critical patent/BR0207310A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA DE INTERFERON GAMA OU DE PIRFENIDONA COM DIAGNóSTICOS MOLECULARES PARA O MELHOR TRATAMENTO DE DOENçAS PULMONARES INTERSTICIAIS". A presente invenção refere-se a uma nova composição farmacêutica que compreende interferon-<sym> ou pirfenidona e um arranjo para diagnóstico de polinucleotídeos candidatos para o tratamento melhorado de doenças pulmonares, especialmente para todas as formas de doenças pulmonares intersticiais. Essa invenção descreve a combinação de diagnósticos moleculares e de terapia clínica como um novo princípio de medicação para a redução da mortalidade e melhoria do controle da doença em doenças pulmonares intersticiais.
BR0207310-2A 2001-12-18 2002-12-12 Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais BR0207310A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01130011 2001-12-18
PCT/CH2002/000691 WO2003051388A2 (en) 2001-12-18 2002-12-12 Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases

Publications (1)

Publication Number Publication Date
BR0207310A true BR0207310A (pt) 2004-08-17

Family

ID=8179579

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207310-2A BR0207310A (pt) 2001-12-18 2002-12-12 Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais

Country Status (9)

Country Link
US (2) US20060270618A1 (pt)
EP (1) EP1455813B1 (pt)
JP (1) JP2005528082A (pt)
CN (1) CN1620309A (pt)
AU (1) AU2002347182A1 (pt)
BR (1) BR0207310A (pt)
CA (1) CA2470763A1 (pt)
NO (1) NO20033642L (pt)
WO (1) WO2003051388A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
BR0207310A (pt) * 2001-12-18 2004-08-17 Mondobiotech Sa Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais
EP1551369A4 (en) * 2002-08-28 2007-05-09 Intermune Inc COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES
EP1644028B1 (de) * 2003-07-14 2009-05-27 mondoBIOTECH AG Substanzen mit biologischer aktivität des vasoaktiven intestinalen peptids für die behandlung von interstitiellen lungenerkrankungen
PT1926813T (pt) * 2005-09-23 2016-09-06 Consejo Superior Investigacion Populações de células que têm atividade imunorreguladora, método para isolamento e usos
CA2634357A1 (en) 2005-12-21 2007-06-28 Basf Se Pharmaceutical formulation for producing rapidly disintegrating tablets
CN101631877A (zh) * 2007-01-09 2010-01-20 百时美施贵宝公司 用于预测可与前列腺细胞中蛋白酪氨酸激酶和/或蛋白酪氨酸激酶途径相互作用和/或对其进行调节的化合物的活性的多核苷酸的鉴定
MX2009013063A (es) 2007-06-06 2010-01-15 Basf Se Formulacion farmaceutica para la produccion de tabletas de desintegracion rapida.
DK2170828T3 (da) * 2007-06-20 2013-03-04 Auspex Pharmaceuticals Inc Substituerede n-aryl pyridinoner som fibrotiske inhibitorer
PT2537529T (pt) 2007-08-02 2018-12-12 Gilead Biologics Inc Anticorpos inibidores de loxl2 e suas utilizações
JP5583592B2 (ja) * 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
CA2747251A1 (en) * 2009-01-26 2010-07-29 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
EP2427575B1 (en) 2009-05-07 2018-01-24 Veracyte, Inc. Methods for diagnosis of thyroid conditions
CA2771774A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. In vitro screening assays
CA2771630A1 (en) * 2009-08-21 2011-02-24 Victoria Smith Therapeutic methods and compositions
EP2467396A4 (en) * 2009-08-21 2012-12-26 Gilead Biologics Inc CATALYTIC DOMAINS FROM LYSYL OXIDASE AND LOXL2
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
CN102711839A (zh) * 2009-08-21 2012-10-03 吉联亚生物科技有限公司 体内筛选试验
US20120329666A1 (en) * 2009-10-05 2012-12-27 Duke University Peripheral Blood Biomarkers for Idiopathic Interstitial Pneumonia and Methods of Use
RU2015108348A (ru) 2010-02-04 2015-07-20 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
AU2011267089B2 (en) 2010-06-14 2017-02-16 Lykera Biomed Sa S100A4 antibodies and therapeutic uses thereof
US10092552B2 (en) 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
WO2014145050A1 (en) 2013-03-15 2014-09-18 Atyr Pharma, Inc. Histidyl-trna synthetase-fc conjugates
CN103467612B (zh) * 2013-09-09 2015-06-24 山东省农业科学院农产品研究所 一种从热榨花生粕中同步提取多糖和蛋白的方法
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
JOP20200115A1 (ar) * 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3215170A4 (en) * 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3344283A1 (en) * 2015-08-31 2018-07-11 Merck Patent GmbH Methods for the modulation of lgals3bp to treat systemic lupus erythematosus
CN107356761B (zh) * 2016-05-09 2020-03-31 上海华盈生物医药科技有限公司 接骨木凝集素及结合珠蛋白相关蛋白的用途
ES2912266T3 (es) 2016-12-23 2022-05-25 Immunogen Inc Inmunoconjugados dirigidos a ADAM9 y procedimientos de uso de los mismos
WO2018119166A1 (en) 2016-12-23 2018-06-28 Macrogenics, Inc. Adam9-binding molecules, and methods of use thereof
CN106860855B (zh) * 2017-03-01 2021-06-11 成都惠泰生物医药有限公司 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
KR102368159B1 (ko) 2017-03-01 2022-03-03 청두 후타이 바이오메디슨 컴퍼니 리미티드 폴리펩티드, 폴리펩티드 단편, 그의 유도체, 및 그의 적용
CN109384830B (zh) * 2017-08-09 2021-12-03 成都惠泰生物医药有限公司 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
WO2018195338A1 (en) * 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN109722455B (zh) * 2017-10-31 2022-03-11 中国科学院天津工业生物技术研究所 微生物发酵生产谷内酯的方法、工程菌及应用
AU2019294510A1 (en) 2018-06-26 2021-01-21 Immunogen, Inc. Immunoconjugates targeting ADAM9 and methods of use thereof
CN111103426B (zh) * 2019-12-19 2022-10-21 广州市妇女儿童医疗中心 Lap3作为儿童腺病毒肺炎诊断标志物的应用
CN113846150B (zh) * 2020-06-28 2024-07-26 深圳华大生命科学研究院 核酸分子及其应用
WO2022192134A1 (en) 2021-03-08 2022-09-15 Immunogen, Inc. Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer
CN114276418B (zh) * 2021-12-28 2024-06-25 中国科学技术大学 一种可用于调控微管、治疗脱髓鞘病变靶向治疗的rna
CN114452376A (zh) * 2022-01-21 2022-05-10 上海市精神卫生中心（上海市心理咨询培训中心） 胰岛素样生长因子结合蛋白2在制备治疗神经脱髓鞘性疾病的药物中的应用
CN114636825B (zh) * 2022-03-02 2022-12-20 中国医学科学院北京协和医院 Golm1作为肺纤维化生物标记物、靶点的应用及检测Golm1的试剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IE873041L (en) * 1987-11-11 1989-05-11 Ailbe Brennan Viral antigens, diagnostic assay therefor and vaccines¹containing them
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
EP1715064B1 (fr) * 1989-06-02 2009-02-25 Institut Pasteur Séquences nucléotidiques issues du génome des rétrovirus du type HIV-1, HIV-2 et SIV, et leurs applications notamment pour l'amplification de séquences de pol de ces génomes de ces rétrovirus et pour le diagnostic in vitro des infections dûes à ces virus
JPH08510251A (ja) * 1993-05-07 1996-10-29 ビー マーゴリン、ソロモン 線維症の病変の修復と予防のための組成物および方法
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
ES2093554B1 (es) * 1995-02-17 1997-07-01 Inst De Salud Carlos Iii Procedimientos de amplificacion de genoma y mezclas de oligonucleotidos iniciadores para la deteccion y la identificacion de agentes infecciosos relacionados.
EP0795332B1 (en) * 1996-03-14 2005-06-01 Mondobiotech Interferon SA Medical use of gamma-interferon in interstitial lung diseases
JP4503844B2 (ja) * 1998-09-24 2010-07-14 イノジェネティックス・ナムローゼ・フェンノートシャップ 急性気道感染（ａｒｉ）を引き起こす微生物の同定
AU779701B2 (en) * 1999-04-02 2005-02-10 Interleukin Genetics, Inc. Prediction of risk of interstitial lung disease
EP1227831A2 (en) * 1999-11-10 2002-08-07 Mondobiotech SA Interferon gamma for the treatment of asthma
EP1231943A1 (en) * 1999-11-12 2002-08-21 Maxygen Holdings Ltd Interferon gamma conjugates
BR0207310A (pt) * 2001-12-18 2004-08-17 Mondobiotech Sa Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais

Also Published As

Publication number Publication date
AU2002347182A1 (en) 2003-06-30
CA2470763A1 (en) 2003-06-26
US20090142301A1 (en) 2009-06-04
EP1455813A2 (en) 2004-09-15
NO20033642D0 (no) 2003-08-15
WO2003051388A3 (en) 2003-10-30
US20060270618A1 (en) 2006-11-30
EP1455813B1 (en) 2015-07-15
NO20033642L (no) 2003-10-17
JP2005528082A (ja) 2005-09-22
CN1620309A (zh) 2005-05-25
WO2003051388A2 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
BR0207310A (pt) Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais
Courneya et al. Physical exercise and quality of life following cancer diagnosis: a literature review
Kleindienst et al. Body self-evaluation and physical scars in patients with borderline personality disorder: an observational study
Karpatkin et al. Effect of a single bout of intermittent versus continuous walking on perceptions of fatigue in people with multiple sclerosis
Yilmaz et al. Energetic and exergetic costs of COVID-19 infection on the body of a patient
Chandnani et al. Group C streptococcus causing rheumatic heart disease in a child
Pawelczyk et al. Pegylated interferon α and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients
ES2915909T3 (es) Citicolina para mejorar la función motora
Kang et al. A study on physical activity and related factors to physical activity for the elderly with diabetes mellitus
Kumar et al. Serotonin syndrome while switching antidepressants
Lyle Medical School Watercooler Newsletter-January 7, 2022
Bawne et al. Case report on infective endocarditis with supravalvular aortic stenosis.
Malta et al. Extracellular matrix distinct signature among dystrophic epidermolysis bullosa variants
Oral et al. Revisiting the management of fatigue in multiple sclerosis in the context of rehabilitation: a narrative review of current evidence
Lou Self-management of cancer treatment-related fatigue, nausea, vomiting and oral mucositis in Chinese cancer patients
Kudrimoti et al. Pediatric solitary cysticercosis in buccal mucosa
Endeman et al. Influence of old age on survival after prolonged mechanical ventilation
Moncrieff et al. The Disease-Centred Model of Drug Action in Psychiatry
Nielsen et al. Cystic hygroma: OK-432 is superior to surgery
Samaria et al. Profile of Nosocomial Pneumonia in Patients with Acute Exacerbation of COPD.
Kauffeldt et al. Identifying effective physical activity guideline dissemination and implementation strategies on health care professionals in a cancer care context: A systematic review
Ortiz et al. Endophthalmitis, pneumonia, and a heart murmur
Scheid et al. CPD: Acute Bacterial Rhinosinusitis in Adults: Part I. Evaluation.
ATE544464T1 (de) Verwendung von g-csf für die behandlung von schlaganfall
Benor Spiritual healing research

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25A Requested transfer of rights approved

Owner name: MONDOBIOTECH LABORATORIES ANSTALT (LI)

Free format text: TRANSFERIDO DE: MONDOBIOTECH INTERFERON SA

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]